Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
09/20/2016 09/21/2016 09/22/2016 09/23/2016 09/26/2016 Date
4.16 4.04 4.11 4.1 4.08 Last
13867 6215 1366 11200 5100 Volume
+1.46% -2.88% +1.73% -0.24% -0.49% Change
Financials ( CAD)
Sales 2016 34,0 M
EBIT 2016 -21,4 M
Net income 2016 -25,0 M
Debt 2016 -
Yield 2016 -
Sales 2017 44,6 M
EBIT 2017 -3,87 M
Net income 2017 -12,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 2,45x
Capi. / Sales2017 1,87x
Capitalization 83,4 M
More Financials
Company
Cardiome Pharma Corp. is a specialty pharmaceutical company.It engages in the discovery, development and commercialization of cardiovascular therapies that will improve the health of patients suffering from heart disease.Cardiome has two marketed products, BRINAVESS, approved in Europe and other... 
Sector
Pharmaceuticals
Calendar
11/04Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
08/16 CARDIOME PHARMA : Announces Recent Insider Purchases
08/09 CARDIOME PHARMA : Announces XYDALBA(TM) Single Dose Infusion Approval by Europea..
08/09 CARDIOME PHARMA : Reports Second Quarter 2016 Financial Results
08/08 CARDIOME PHARMA : Announces the Addition of Two Key Members to its Management Te..
08/03 CARDIOME PHARMA : to Hold Second Quarter 2016 Financial Results Conference Call ..
07/29 CARDIOME PHARMA : Closes Public Offering of 11,500,000 Common Shares
07/26 CARDIOME PHARMA : Announces Pricing of Public Offering of 10,000,000 Common Shar..
07/25 CARDIOME PHARMA : Announces Proposed Public Offering of Common Shares
07/18 CARDIOME PHARMA : Veritas Provides Investor Update
07/14 CARDIOME PHARMA : ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimb..
More news
Sector news : Biopharmaceuticals
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
More sector news : Biopharmaceuticals
News from SeekingAlpha
08/10 Cardiome Pharma's (CRME) CEO Bill Hunter on Q2 2016 Results - Earnings Call T..
08/10 Single-dose regimen for Cardiome's Xydalba OK'd in Europe
08/09 Cardiome Pharma misses by $0.18, misses on revenue
08/08 Notable earnings after Tuesday?s close
07/26 FINANCIALS - TOP 5 GAINERS / LOSERS : 00 pm
Advertisement
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 177%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Harold H. Shlevin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-61.36%64
CSL LIMITED0.33%36 850
ALEXION PHARMACEUTICAL..-34.73%28 529
GRIFOLS SA-8.75%13 519
BEIJING TIANTAN BIOLOG..10.39%2 981
3SBIO INC-21.02%2 835
More Results